A5049481601- Multiple Sclerosis Research Studies
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Autoimmune and Inflammatory Disorders Research
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- Neuroinflammation and Neurodegeneration Mechanisms
- Hepatitis Viruses Studies and Epidemiology
- Hepatitis C virus research
- Systemic Lupus Erythematosus Research
- Vaccine Coverage and Hesitancy
- Retinal and Optic Conditions
- Sphingolipid Metabolism and Signaling
- Botulinum Toxin and Related Neurological Disorders
- Viral gastroenteritis research and epidemiology
- Virology and Viral Diseases
Federico II University Hospital
2018-2022
University of Naples Federico II
2019-2022
In multiple sclerosis (MS), disease-related factors and dysfunctional coping might favor the development of mental distress induced by COVID-19 containment measures. Aim this study was exploring relationship between disability, strategies, daily life reorganization neuropsychiatric symptoms in an Italian MS population during lockdown, order to identify potentially modifiable that could inform clinical management people with MS.We explored distress, disability strategies under lockdown....
Background: To evaluate retinal vessel density (VD) in macular and peripapillary regions patients with recent onset of multiple sclerosis, at initial demyelinating event (IDE) matched relapsing-remitting sclerosis (RRMS) patients. Methods: We evaluated VD superficial capillary plexus, deep choriocapillaris radial plexus IDE, RRMS healthy controls (HCs) through Optical Coherence Tomography Angiography (OCT-A). Clinical history, including history optic neuritis, Expanded Disability Status...
Abstract Background and purpose Cardiovascular risk factors comorbidities can affect the prognosis of multiple sclerosis (MS). The Framingham score is an algorithm that estimate 10‐year developing macrovascular disease. Our objectives were to evaluate possible association between at baseline MS relapses, disability, disease‐modifying therapy (DMT) choices over a 5‐year follow‐up. Methods This retrospective cohort study including 251 subjects. At baseline, we calculated considering following...
Physical disability impacts psychosocial wellbeing in people with multiple sclerosis. However, the role of physical activity this context is still debated. By taking advantage a previous survey, conducted online from 22 April to 7 May 2020, we performed post-hoc analysis aim assess associations between disability, exercise, and mental health We retrieved following data: (i) sociodemographic information, (ii) changes lifestyle (including exercise), (iii) as measured Patient-Determined Disease...
Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed evaluate the MS Centers behavior regarding HBV screening and prophylaxis in a large cohort patients receiving anti-CD20 or cladribine.
Abstract Background Cognitive impairment occurs in multiple sclerosis (MS) and undergoes a progressive worsening over disease course. However, clinicians still struggle to predict the course of cognitive function. To evaluate baseline clinical imaging predictors abilities time, we performed latent trajectory analysis for performances MS patients, up 15 years from onset. Methods We collected age, sex, education, dominant non-dominant 9-hole peg test (9HP) timed 25-foot walk (T25-FW) as well...
We aim to validate a case-finding algorithm detect individuals with multiple sclerosis (MS) using routinely collected healthcare data, and assess the prevalence of MS in Campania Region (South Italy). To identify living Region, we employed an different administrative databases (hospital discharges, drug prescriptions, outpatient consultations payment exemptions), from 1 January 2015 31 December 2017. The was validated towards clinical registry largest regional centre (n = 1460). used direct...
Cardiovascular comorbidities have been associated with cognitive decline in the general population.
Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it also effective on disability progression. In present single-center study, we aim to report 8-years clinical follow-up 27 patients included in phase 2 and 3 trials cladribine. Methods: We exposed cladribine (n = 13) or placebo 14) ONWARD, CLARITY, ORACLE-MS trials, followed-up at same center after trial termination. Outcomes long-term disease progression were recorded. Results:...
Pivotal trials showed the effectiveness of monoclonal antibody ocrelizumab in relapsing and progressive multiple sclerosis (MS). However, data on everyday practice MS patients markers treatment are scarce. We aimed to collect real-world from ocrelizumab-treated patients, relapsing-remitting (RR) (PMS), including active secondary (aSPMS) primary (PPMS) explore potential prognostic factors clinical outcome. Patients were enrolled at centres Campania region, Italy. collected clinic-demographic...
Diagnostics of Multiple Sclerosis (MS) are essentially based on the gold standard magnetic resonance imaging. Few alternative simple assays available to follow up disease activity. Considering that can remain elusive for years, identification antibodies fluctuating in biological fluids as relevant biomarkers immune response is a challenge. In previous studies, we reported anti-N-glucosylated (N-Glc) peptide be easily detected Solid-Phase Enzyme-Linked ImmunoSorbent Assays (SP-ELISA) MS...
In this issue of EBioMedicine, Chen and colleagues investigated the association between urate, anionic form uric acid, blood pressure (BP), by studying three groups genetically engineered mice with different levels reanalysing data from a clinical trial using inosine to increase urate in Parkinson's disease (PD) [[1]The Parkinson Study Group SURE-PD Investigators Inosine serum cerebrospinal fluid parkinson randomized trial.JAMA Neurol. 2014; 71: 141-150Crossref PubMed Scopus (181) Google...
Abstract The authors have requested removal of this preprint.